Transfusion Journal/ transfusion.org
Aug 28, 2025, 18:54
Albert Farrugia: When Will FV Deficiency Get the Attention It Deserves?
Albert Farrugia, Clinical professor at The University of Western Australia, shared an insightful post on LinkedIn:
“The largest series, as far as I’m aware, on the use of FX concentrate in this extremely rare deficiency.
When are we going to see some effort for FV deficiency. I anticipate efficacy with many of the bypassing agents.
It’s disappointing not to see FV deficient patients included in the trials.
Read the full article:”
Article: Characterization and management of patients with hereditary factor X deficiency: A case series
Authors: Meera Chitlur, Lauren E. Amos, Mark T. Reding, Cynthia Sabo, Suchitra S. Acharya
Stay updated with Haemostasis Today.
-
Oct 19, 2026, 11:37Beth Faiman: APSHO Fellows Celebrated for Advancing Hematology and Oncology Practice
-
Oct 19, 2026, 11:26Emanuele Pacini: Myelodysplastic Syndromes Research Featured at JSH Annual Meeting in Kyoto
-
Oct 19, 2026, 10:57Jesmond Dalli: How Erythroblasts Shape Neutrophil Development and Function
-
Oct 19, 2026, 10:41Hisham Fahmi: SCD – Should Gene Editing Begin Before Organ Damage?
-
Oct 19, 2026, 10:33Pallavi Madhiraju: YARTEMLEA Faces Another European Rejection Despite FDA Approval
-
Oct 19, 2026, 10:28Brig Tathagata Chatterjee: Acute Leukemias in AYAs at the Japanese Society of Hematology Conference
-
Oct 19, 2026, 10:27Heather M. Johnson: Join the Discussion on Optimizing the CTEPH Diagnostic Pathway
-
Oct 19, 2026, 10:18Flora Peyvandi: Unravelling the Complexity of VWF Through Genetics
-
Oct 19, 2026, 09:55High DOAC Adherence in Patients With Ischemic Stroke and AF – International Journal of Stroke